Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 13 | 2023 | 312 | 2.420 |
Why?
|
| Kidney Diseases | 4 | 2020 | 169 | 1.280 |
Why?
|
| Kidney Failure, Chronic | 7 | 2019 | 206 | 1.190 |
Why?
|
| Renal Dialysis | 2 | 2021 | 189 | 0.760 |
Why?
|
| Graft Survival | 4 | 2023 | 290 | 0.730 |
Why?
|
| Immunosuppressive Agents | 4 | 2021 | 365 | 0.720 |
Why?
|
| Nephrology | 1 | 2020 | 15 | 0.700 |
Why?
|
| Paraproteinemias | 2 | 2010 | 17 | 0.660 |
Why?
|
| Anticoagulants | 1 | 2021 | 477 | 0.560 |
Why?
|
| Abatacept | 1 | 2016 | 64 | 0.510 |
Why?
|
| Cyclosporine | 1 | 2016 | 76 | 0.500 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2019 | 328 | 0.420 |
Why?
|
| Acute Kidney Injury | 1 | 2013 | 132 | 0.370 |
Why?
|
| Multiple Myeloma | 2 | 2013 | 325 | 0.360 |
Why?
|
| Myeloablative Agonists | 1 | 2010 | 14 | 0.360 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2009 | 17 | 0.320 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2010 | 113 | 0.320 |
Why?
|
| Cathartics | 1 | 2008 | 8 | 0.300 |
Why?
|
| Colonic Polyps | 1 | 2008 | 25 | 0.300 |
Why?
|
| Adenoma | 1 | 2008 | 64 | 0.290 |
Why?
|
| Colonoscopy | 1 | 2008 | 86 | 0.290 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 54 | 0.290 |
Why?
|
| Phosphates | 1 | 2008 | 90 | 0.290 |
Why?
|
| Living Donors | 3 | 2023 | 71 | 0.270 |
Why?
|
| Graft Rejection | 3 | 2023 | 289 | 0.250 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 263 | 0.240 |
Why?
|
| HLA Antigens | 2 | 2023 | 61 | 0.230 |
Why?
|
| Humans | 21 | 2023 | 59285 | 0.210 |
Why?
|
| Immunoglobulins | 2 | 2013 | 76 | 0.180 |
Why?
|
| Histocompatibility | 1 | 2021 | 8 | 0.180 |
Why?
|
| Isoantibodies | 1 | 2021 | 33 | 0.180 |
Why?
|
| Forecasting | 1 | 2020 | 219 | 0.160 |
Why?
|
| Transplantation, Haploidentical | 1 | 2019 | 3 | 0.160 |
Why?
|
| Transplant Recipients | 2 | 2016 | 31 | 0.160 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 44 | 0.150 |
Why?
|
| Biopsy | 3 | 2009 | 411 | 0.150 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2018 | 14 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2021 | 5283 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 326 | 0.140 |
Why?
|
| Risk Factors | 6 | 2023 | 4982 | 0.130 |
Why?
|
| Simeprevir | 1 | 2016 | 6 | 0.130 |
Why?
|
| Sofosbuvir | 1 | 2016 | 18 | 0.130 |
Why?
|
| Ribavirin | 1 | 2016 | 24 | 0.130 |
Why?
|
| Sirolimus | 1 | 2016 | 88 | 0.130 |
Why?
|
| Organ Transplantation | 1 | 2016 | 53 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 687 | 0.120 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 88 | 0.120 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 162 | 0.120 |
Why?
|
| Levofloxacin | 1 | 2014 | 12 | 0.110 |
Why?
|
| Viremia | 1 | 2014 | 44 | 0.110 |
Why?
|
| Tumor Virus Infections | 1 | 2014 | 37 | 0.110 |
Why?
|
| BK Virus | 1 | 2014 | 24 | 0.110 |
Why?
|
| Polyomavirus Infections | 1 | 2014 | 46 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2016 | 311 | 0.110 |
Why?
|
| Plasma Exchange | 1 | 2013 | 21 | 0.110 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 75 | 0.100 |
Why?
|
| Mannitol | 1 | 2012 | 14 | 0.100 |
Why?
|
| Complement C5 | 1 | 2012 | 8 | 0.100 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2012 | 5 | 0.100 |
Why?
|
| Middle Aged | 10 | 2023 | 16311 | 0.100 |
Why?
|
| Hypotension | 1 | 2012 | 48 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2014 | 143 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 404 | 0.090 |
Why?
|
| Adult | 8 | 2023 | 15664 | 0.090 |
Why?
|
| Time Factors | 3 | 2021 | 3614 | 0.090 |
Why?
|
| Morbidity | 1 | 2010 | 112 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 219 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2012 | 495 | 0.080 |
Why?
|
| Bence Jones Protein | 1 | 2009 | 2 | 0.080 |
Why?
|
| Anemia | 1 | 2010 | 119 | 0.080 |
Why?
|
| Plasma Cells | 1 | 2009 | 49 | 0.080 |
Why?
|
| Hypophosphatemia, Familial | 1 | 2008 | 5 | 0.080 |
Why?
|
| Nephrocalcinosis | 1 | 2008 | 6 | 0.080 |
Why?
|
| Aged | 6 | 2023 | 13412 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 631 | 0.070 |
Why?
|
| Male | 10 | 2021 | 27727 | 0.070 |
Why?
|
| Recurrence | 1 | 2009 | 602 | 0.070 |
Why?
|
| Delayed Graft Function | 2 | 2021 | 4 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2008 | 180 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2008 | 356 | 0.070 |
Why?
|
| Peritonitis, Tuberculous | 1 | 2006 | 3 | 0.070 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2006 | 5 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 806 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 442 | 0.060 |
Why?
|
| Registries | 2 | 2021 | 801 | 0.060 |
Why?
|
| Female | 9 | 2021 | 30696 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 837 | 0.060 |
Why?
|
| Creatinine | 2 | 2014 | 128 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2021 | 6071 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 2337 | 0.050 |
Why?
|
| United States | 3 | 2021 | 7385 | 0.040 |
Why?
|
| Young Adult | 2 | 2023 | 4266 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2019 | 98 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2016 | 2372 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2018 | 48 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 332 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 914 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 100 | 0.030 |
Why?
|
| Animals | 1 | 2013 | 19601 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 452 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1078 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 674 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2019 | 1202 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 1920 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 1599 | 0.030 |
Why?
|
| Viral Load | 1 | 2014 | 219 | 0.030 |
Why?
|
| Linear Models | 1 | 2014 | 402 | 0.030 |
Why?
|
| Adolescent | 1 | 2023 | 5822 | 0.030 |
Why?
|
| Diuretics, Osmotic | 1 | 2012 | 1 | 0.030 |
Why?
|
| Hypertonic Solutions | 1 | 2012 | 5 | 0.030 |
Why?
|
| Membrane Cofactor Protein | 1 | 2012 | 2 | 0.020 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2012 | 5 | 0.020 |
Why?
|
| Complement Factor B | 1 | 2012 | 11 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 2012 | 37 | 0.020 |
Why?
|
| Complement Factor I | 1 | 2012 | 9 | 0.020 |
Why?
|
| Proteinuria | 1 | 2012 | 38 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 715 | 0.020 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2011 | 4 | 0.020 |
Why?
|
| Pleural Neoplasms | 1 | 1991 | 19 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 2011 | 22 | 0.020 |
Why?
|
| Hemostasis, Surgical | 1 | 2011 | 17 | 0.020 |
Why?
|
| Mesothelioma | 1 | 1991 | 27 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2012 | 230 | 0.020 |
Why?
|
| Complement System Proteins | 1 | 2012 | 114 | 0.020 |
Why?
|
| Complement Factor H | 1 | 2012 | 129 | 0.020 |
Why?
|
| Postoperative Hemorrhage | 1 | 2011 | 37 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 788 | 0.020 |
Why?
|
| Pneumonectomy | 1 | 1991 | 96 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1305 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 3065 | 0.020 |
Why?
|
| Peritoneum | 1 | 2006 | 27 | 0.020 |
Why?
|
| Neoplasms | 1 | 2016 | 1240 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2006 | 259 | 0.010 |
Why?
|
| Tuberculosis | 1 | 2006 | 270 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2006 | 390 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 635 | 0.010 |
Why?
|
| Pleura | 1 | 1991 | 13 | 0.010 |
Why?
|
| Diaphragm | 1 | 1991 | 21 | 0.010 |
Why?
|
| Pericardium | 1 | 1991 | 35 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1991 | 355 | 0.010 |
Why?
|
| Survival Rate | 1 | 1991 | 802 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1991 | 406 | 0.000 |
Why?
|